In this month’s edition of Clinical Lymphoma, Myeloma & Leukemia, Zhuang et al provide an insightful review on the affect that polymorphic variants in Fcγ receptors (FcγRs) play in predicting response outcome in patients with non-Hodgkin lymphoma (NHL) who receive rituximab therapy.1 The paper nicely outlines the potential role and limitations of predictive genomics involving FcγR polymorphisms (Figure 1). Since the report by Cartron et al in 2002 showing that polymorphisms in FcγRIIIA-158 were associated with response to rituximab in patients with follicular NHL, a number of interesting queries have arisen on just how polymorphic FcγR testing could be used in the real-world practice of hematologists and oncologists.2 These queries have included: